161 related articles for article (PubMed ID: 26164177)
1. Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET/CT.
Bacanovic S; Burger IA; Stolzmann P; Hafner J; Huellner MW
Clin Nucl Med; 2015 Nov; 40(11):e518-9. PubMed ID: 26164177
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab-induced hepatitis on 18F-FDG PET/CT in a patient with malignant melanoma.
Raad RA; Pavlick A; Kannan R; Friedman KP
Clin Nucl Med; 2015 Mar; 40(3):258-9. PubMed ID: 25290291
[TBL] [Abstract][Full Text] [Related]
3. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.
Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022
[TBL] [Abstract][Full Text] [Related]
5. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
van der Hiel B; Blank CU; Haanen JB; Stokkel MP
Clin Nucl Med; 2013 Apr; 38(4):e182-4. PubMed ID: 23455528
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study.
Sachpekidis C; Larribere L; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):386-96. PubMed ID: 25359635
[TBL] [Abstract][Full Text] [Related]
7. Ipilimumab-induced colitis on FDG PET/CT.
Lyall A; Vargas HA; Carvajal RD; Ulaner G
Clin Nucl Med; 2012 Jun; 37(6):629-30. PubMed ID: 22614208
[TBL] [Abstract][Full Text] [Related]
8. Anti-CTLA4 antibody therapy related complications on FDG PET/CT.
Koo PJ; Klingensmith WC; Lewis KD; Bagrosky BM; Gonzalez R
Clin Nucl Med; 2014 Jan; 39(1):e93-6. PubMed ID: 23657138
[TBL] [Abstract][Full Text] [Related]
9. Absolute number of new lesions on
Anwar H; Sachpekidis C; Winkler J; Kopp-Schneider A; Haberkorn U; Hassel JC; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):376-383. PubMed ID: 29124281
[TBL] [Abstract][Full Text] [Related]
10. Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT.
Alabed YZ; Aghayev A; Sakellis C; Van den Abbeele AD
Clin Nucl Med; 2015 Nov; 40(11):e528-9. PubMed ID: 26284765
[TBL] [Abstract][Full Text] [Related]
11. Unusual diffuse liver
Muteganya R; Karfis I; Artigas C; Garcia C; Francesco F; Kerger J; Flamen P
Hell J Nucl Med; 2017; 20(2):179-181. PubMed ID: 28697198
[TBL] [Abstract][Full Text] [Related]
12. [Multiple enlarged metabolically active lymph nodes in 18F-FDG PET/CT after anti-CTLA-4 antibody therapy in metastatic melanoma - disease progression or immunologically induced side effect?].
Schüle SC; Eigentler T; Pfannenberg C
Rofo; 2015 Nov; 187(11):1036-7. PubMed ID: 26062178
[No Abstract] [Full Text] [Related]
13. Umbilical Plugoma Mimics Melanoma Metastasis on FDG PET/CT.
Alabed YZ; Sakellis C
Clin Nucl Med; 2015 Oct; 40(10):812-3. PubMed ID: 26164172
[TBL] [Abstract][Full Text] [Related]
14. (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.
Perng P; Marcus C; Subramaniam RM
AJR Am J Roentgenol; 2015 Aug; 205(2):259-70. PubMed ID: 26204273
[TBL] [Abstract][Full Text] [Related]
15. Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma.
O'Kane GM; Lyons TG; Colleran GC; Ahmad MW; Alken S; Kavanagh EC; Fitzpatrick D; Murray B; Kelly CM
Oncol Res Treat; 2014; 37(12):757-60. PubMed ID: 25531722
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC
Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029
[TBL] [Abstract][Full Text] [Related]
17. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
[TBL] [Abstract][Full Text] [Related]
18. Solitary subcutaneous gouty nodule mimicking metastatic melanoma on FDG PET/CT.
Edwards KW; Doss M; Huang M; Hayes SB; Walia R; Yu JQ
Clin Nucl Med; 2015 Jun; 40(6):523-5. PubMed ID: 25608170
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab-induced immunomediated adverse events: possible pitfalls in (18)F-FDG PET/CT interpretation.
Gilardi L; Colandrea M; Vassallo S; Travaini LL; Paganelli G
Clin Nucl Med; 2014 May; 39(5):472-4. PubMed ID: 23640225
[TBL] [Abstract][Full Text] [Related]
20. High False Positivity in Positron Emission Tomography is a Potential Diagnostic Pitfall in Patients with Suspected Adrenal Metastasis.
Lang BH; Cowling BJ; Li JY; Wong KP; Wan KY
World J Surg; 2015 Aug; 39(8):1902-8. PubMed ID: 25809060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
